HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,432,271 | +4.4% | 37,494 | -1.4% | 0.01% | +9.1% |
| Q2 2023 | $1,371,922 | -8.3% | 38,035 | -2.9% | 0.01% | -15.4% |
| Q1 2023 | $1,496,208 | -32.4% | 39,178 | +0.8% | 0.01% | -38.1% |
| Q4 2022 | $2,212,158 | +49.3% | 38,878 | +3.7% | 0.02% | +40.0% |
| Q3 2022 | $1,482,000 | -9.7% | 37,488 | +0.5% | 0.02% | -6.2% |
| Q2 2022 | $1,642,000 | +13.9% | 37,318 | +3.2% | 0.02% | +33.3% |
| Q1 2022 | $1,442,000 | -1.4% | 36,154 | -0.7% | 0.01% | +9.1% |
| Q4 2021 | $1,463,000 | -2.4% | 36,394 | -1.2% | 0.01% | -8.3% |
| Q3 2021 | $1,499,000 | -5.5% | 36,846 | +5.5% | 0.01% | -7.7% |
| Q2 2021 | $1,586,000 | +1.7% | 34,933 | -6.6% | 0.01% | -7.1% |
| Q1 2021 | $1,559,000 | -3.3% | 37,384 | -1.0% | 0.01% | -6.7% |
| Q4 2020 | $1,612,000 | +57.6% | 37,751 | -3.0% | 0.02% | +50.0% |
| Q3 2020 | $1,023,000 | +28.7% | 38,930 | +31.3% | 0.01% | -9.1% |
| Q2 2020 | $795,000 | +42.7% | 29,639 | -4.3% | 0.01% | +10.0% |
| Q1 2020 | $557,000 | – | 30,962 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $191,226,000 | 8.73% |
| BB BIOTECH AG | 6,825,532 | $65,866,000 | 2.13% |
| Lombard Odier Asset Management (USA) Corp | 2,700,000 | $26,055,000 | 1.79% |
| SECTORAL ASSET MANAGEMENT INC | 3,724,351 | $35,940,000 | 1.61% |
| QVT Financial LP | 2,010,186 | $19,398,000 | 0.97% |
| JHL Capital Group LLC | 1,475,000 | $14,234,000 | 0.94% |
| MAZAMA CAPITAL MANAGEMENT INC | 358,087 | $3,456,000 | 0.79% |
| EcoR1 Capital, LLC | 160,700 | $1,551,000 | 0.78% |
| Alden Global Capital Ltd | 332,500 | $3,209,000 | 0.77% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 7,274,065 | $70,195,000 | 0.65% |